Clinical Trials

Our clinic trial news comes directly from the U.S. National Institutes of Health.   If you have additional trial information please post it to our website or let us know by email.

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion
Sponsor:   St. Jude Children's Research Hospital

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

Condition:   Sporadic Amyotrophic Lateral Sclerosis
Interventions:   Drug: Mexiletine;   Drug: Placebo
Sponsors:   University of Washington;   Massachusetts General Hospital
Recruiting - verified December 2016

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Condition:   Severe Aplastic Anemia
Interventions:   Drug: cyclosporine;   Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;   Drug: horse anti-thymocyte globulin (ATG);   Drug: rabbit anti-thymocyte globulin (ATG);   Drug: methotrexate;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: low-dose total body irradiation (TBI);   Procedure: Immunosuppressive Therapy (IST)
Sponsor:   Andrew Dietz
Recruiting - verified August 2016

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Condition:   Sickle Cell Disease
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program
Recruiting - verified February 2017

Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Condition:   Sickle Cell Disease
Interventions:   Procedure: Bone Marrow Transplant (BMT);   Procedure: Bone Marrow Harvest (Donation);   Drug: Hydroxyurea;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Other: Rabbit Anti-thymocyte Globulin;   Radiation: Total Body Irradiation
Sponsor:   Emory University
Recruiting - verified December 2016

Pages